ALS drug gets rare second review at high-stakes FDA meeting

A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup